P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT
Anjali Cremer,
Julius C. Enssle,
Saskia Pfaff,
Khouloud Kouidri,
Fabian Lang,
Christian Brandts,
Andreas Zeiher,
Sebastian Cremer,
Björn Steffen,
Hubert Serve,
Gesine Bug
Affiliations
Anjali Cremer
1 University Hospital Frankfurt, Hematology/Oncology, Frankfurt, Germany
Julius C. Enssle
1 University Hospital Frankfurt, Hematology/Oncology, Frankfurt, Germany
Saskia Pfaff
1 University Hospital Frankfurt, Hematology/Oncology, Frankfurt, Germany
Khouloud Kouidri
1 University Hospital Frankfurt, Hematology/Oncology, Frankfurt, Germany
Fabian Lang
1 University Hospital Frankfurt, Hematology/Oncology, Frankfurt, Germany
Christian Brandts
1 University Hospital Frankfurt, Hematology/Oncology, Frankfurt, Germany
Andreas Zeiher
2 University Hospital Frankfurt, Cardiology, Frankfurt, Germany
Sebastian Cremer
2 University Hospital Frankfurt, Cardiology, Frankfurt, Germany
Björn Steffen
1 University Hospital Frankfurt, Hematology/Oncology, Frankfurt, Germany
Hubert Serve
1 University Hospital Frankfurt, Hematology/Oncology, Frankfurt, Germany
Gesine Bug
1 University Hospital Frankfurt, Hematology/Oncology, Frankfurt, Germany
